SEARCH

SEARCH BY CITATION

References

  • Allen, J.A., Halverson-Tamboli, R.A. & Rasenick, M.M. (2007) Lipid raft microdomains and neurotransmitter signalling. Nature Reviews Neuroscience, 8, 128140.
  • Anderson, R.G. & Jacobson, K. (2002) A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. Science, 296, 18211825.
  • Awasthi-Kalia, M., Schnetkamp, P.P. & Deans, J.P. (2001) Differential effects of filipin and methyl-beta-cyclodextrin on B cell receptor signaling. Biochemical and Biophysical Research Communications, 287, 7782.
  • Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., Scott, M.A., Erber, W.N. & Green, A.R. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 10541061.
  • Brown, D.A. (2006) Lipid rafts, detergent-resistant membranes, and raft targeting signals. Physiology, 21, 430439.
  • Dai, Y., Khanna, P., Chen, S., Pei, X.Y., Dent, P. & Grant, S. (2007) Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation. Blood, 109, 44154423.
  • Dawson, M.A., Bannister, A.J., Gottgens, B., Foster, S.D., Bartke, T., Green, A.R. & Kouzarides, T. (2009) JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature, 461, 819822.
  • Demierre, M.F., Higgins, P.D., Gruber, S.B., Hawk, E. & Lippman, S.M. (2005) Statins and cancer prevention. Nature Reviews Cancer, 5, 930942.
  • Dimitroulakos, J., Nohynek, D., Backway, K.L., Hedley, D.W., Yeger, H., Freedman, M.H., Minden, M.D. & Penn, L.Z. (1999) Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood, 93, 13081318.
  • Edidin, M. (2001) Shrinking patches and slippery rafts: scales of domains in the plasma membrane. Trends in Cell Biology, 11, 492496.
  • Ferro, D., Parrotto, S., Basili, S., Alessandri, C. & Violi, F. (2000) Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. Journal of the American College of Cardiology, 36, 427431.
  • Fleischman, A.G., Aichberger, K.J., Luty, S.B., Bumm, T.G., Petersen, C.L., Doratotaj, S., Vasudevan, K.B., LaTocha, D.H., Yang, F., Press, R.D., Loriaux, M.M., Pahl, H.L., Silver, R.T., Agarwal, A., O'Hare, T., Druker, B.J., Bagby, G.C. & Deininger, M.W. (2011) TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood, 118, 63926398.
  • Frederiksen, H., Farkas, D.K., Christiansen, C.F., Hasselbalch, H.C. & Sorensen, H.T. (2011) Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood, 118, 65156520.
  • Galbiati, F., Razani, B. & Lisanti, M.P. (2001) Emerging themes in lipid rafts and caveolae. Cell, 106, 403411.
  • Hamadmad, S.N. & Hohl, R.J. (2007) Lovastatin suppresses erythropoietin receptor surface expression through dual inhibition of glycosylation and geranylgeranylation. Biochemical Pharmacology, 74, 590600.
  • Hantschel, O., Warsch, W., Eckelhart, E., Kaupe, I., Grebien, F., Wagner, K.U., Superti-Furga, G. & Sexl, V. (2012) BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nature Chemical Biology, 8, 285293.
  • Harder, T. & Simons, K. (1997) Caveolae, DIGs, and the dynamics of sphingolipid-cholesterol microdomains. Current Opinion in Cell Biology, 9, 534542.
  • Hasselbalch, H.C. (2012) Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood, 119, 32193225.
  • Hasselbalch, H.C. & Riley, C.H. (2006) Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential? Leukemia Research, 30, 12171225.
  • James, C., Ugo, V., Le Couedic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. & Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 11441148.
  • Jatiani, S.S., Baker, S.J., Silverman, L.R. & Reddy, E.P. (2010) Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes and Cancer, 1, 979993.
  • Jedidi, A., Marty, C., Oligo, C., Jeanson-Leh, L., Ribeil, J.A., Casadevall, N., Galy, A., Vainchenker, W. & Villeval, J.L. (2009) Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines. Blood, 114, 18421851.
  • Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. & Skoda, R.C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. The New England Journal of Medicine, 352, 17791790.
  • Kurzchalia, T.V. & Parton, R.G. (1999) Membrane microdomains and caveolae. Current Opinion in Cell Biology, 11, 424431.
  • Lee, T.S., Ma, W., Zhang, X., Giles, F., Kantarjian, H. & Albitar, M. (2009) Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations. Cancer, 115, 16921700.
  • Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J., Boggon, T.J., Wlodarska, I., Clark, J.J., Moore, S., Adelsperger, J., Koo, S., Lee, J.C., Gabriel, S., Mercher, T., D'Andrea, A., Frohling, S., Dohner, K., Marynen, P., Vandenberghe, P., Mesa, R.A., Tefferi, A., Griffin, J.D., Eck, M.J., Sellers, W.R., Meyerson, M., Golub, T.R., Lee, S.J. & Gilliland, D.G. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387397.
  • Levine, R.L., Pardanani, A., Tefferi, A. & Gilliland, D.G. (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nature Reviews Cancer, 7, 673683.
  • Lu, X., Levine, R., Tong, W., Wernig, G., Pikman, Y., Zarnegar, S., Gilliland, D.G. & Lodish, H. (2005) Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proceedings of the National Academy of Sciences USA, 102, 1896218967.
  • Lu, X., Huang, L.J. & Lodish, H.F. (2008) Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. The Journal of Biological Chemistry, 283, 52585266.
  • McGraw, K.L., Fuhler, G.M., Johnson, J.O., Clark, J.A., Caceres, G.C., Sokol, L. & List, A.F. (2012) Erythropoietin receptor signaling is membrane raft dependent. PLoS ONE, 7, e34477.
  • Monastyrskaya, K., Hostettler, A., Buergi, S. & Draeger, A. (2005) The NK1 receptor localizes to the plasma membrane microdomains, and its activation is dependent on lipid raft integrity. The Journal of Biological Chemistry, 280, 71357146.
  • Newman, A., Clutterbuck, R.D., Powles, R.L., Catovsky, D. & Millar, J.L. (1997) A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors. Leukemia & Lymphoma, 24, 533537.
  • Oh, S.T. & Gotlib, J. (2010) JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Review of Hematology, 3, 323337.
  • Ostermeyer, A.G., Beckrich, B.T., Ivarson, K.A., Grove, K.E. & Brown, D.A. (1999) Glycosphingolipids are not essential for formation of detergent-resistant membrane rafts in melanoma cells. methyl-beta-cyclodextrin does not affect cell surface transport of a GPI-anchored protein. The Journal of Biological Chemistry, 274, 3445934466.
  • Pardanani, A., Vannucchi, A.M., Passamonti, F., Cervantes, F., Barbui, T. & Tefferi, A. (2011) JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia, 25, 218225.
  • Pralle, A., Keller, P., Florin, E.L., Simons, K. & Horber, J.K. (2000) Sphingolipid-cholesterol rafts diffuse as small entities in the plasma membrane of mammalian cells. Journal of Cell Biology, 148, 9971008.
  • Prchal, J.F. & Axelrad, A.A. (1974) Letter: bone-marrow responses in polycythemia vera. The New England Journal of Medicine, 290, 1382.
  • Quentmeier, H., MacLeod, R.A., Zaborski, M. & Drexler, H.G. (2006) JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia, 20, 471476.
  • Rinaldi, C.R., Rinaldi, P., Alagia, A., Gemei, M., Esposito, N., Formiggini, F., Martinelli, V., Senyuk, V., Nucifora, G. & Pane, F. (2010) Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytic, or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia. Blood, 116, 60236026.
  • Scheiffele, P., Rietveld, A., Wilk, T. & Simons, K. (1999) Influenza viruses select ordered lipid domains during budding from the plasma membrane. The Journal of Biological Chemistry, 274, 20382044.
  • Scherber, R. & Mesa, R.A. (2011) Future therapies for the myeloproliferative neoplasms. Current Hematologic Malignancy Reports, 6, 2227.
  • Scott, L.M., Tong, W., Levine, R.L., Scott, M.A., Beer, P.A., Stratton, M.R., Futreal, P.A., Erber, W.N., McMullin, M.F., Harrison, C.N., Warren, A.J., Gilliland, D.G., Lodish, H.F. & Green, A.R. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. The New England Journal of Medicine, 356, 459468.
  • Sehgal, P.B. (2003) Plasma membrane rafts and chaperones in cytokine/STAT signaling. Acta Biochimica Polonica, 50, 583594.
  • Simons, K. & Ikonen, E. (1997) Functional rafts in cell membranes. Nature, 387, 569572.
  • Simons, K. & Toomre, D. (2000) Lipid rafts and signal transduction. Nature Reviews Molecular Cell Biology, 1, 3139.
  • Tefferi, A. (2012) JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood, 119, 27212730.
  • Vannucchi, A.M., Masala, G., Antonioli, E., Chiara Susini, M., Guglielmelli, P., Pieri, L., Maggi, L., Caini, S., Palli, D., Bogani, C., Ponziani, V., Pancrazzi, A., Annunziato, F. & Bosi, A. (2009) Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiology Biomarkers and Prevention, 18, 20682073.
  • Waheed, A.A. & Freed, E.O. (2009) Lipids and membrane microdomains in HIV1 replication. Virus Research, 143, 162176.
  • Walz, C., Crowley, B.J., Hudon, H.E., Gramlich, J.L., Neuberg, D.S., Podar, K., Griffin, J.D. & Sattler, M. (2006) Activated Jak2 with the V617F point mutation promotes G1/S phase transition. The Journal of Biological Chemistry, 281, 1817718183.
  • Weng, T.C., Yang, Y.H., Lin, S.J. & Tai, S.H. (2010) A systematic review and meta-analysis on the therapeutic equivalence of statins. Journal of Clinical Pharmacy and Therapeutics, 35, 139151.
  • Witthuhn, B.A., Quelle, F.W., Silvennoinen, O., Yi, T., Tang, B., Miura, O. & Ihle, J.N. (1993) JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell, 74, 227236.
  • Xie, S., Wang, Y., Liu, J., Sun, T., Wilson, M.B., Smithgall, T.E. & Arlinghaus, R.B. (2001) Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene, 20, 61886195.
  • Yvan-Charvet, L., Pagler, T., Gautier, E.L., Avagyan, S., Siry, R.L., Han, S., Welch, C.L., Wang, N., Randolph, G.J., Snoeck, H.W. & Tall, A.R. (2010) ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science, 328, 16891693.
  • Zhao, R., Xing, S., Li, Z., Fu, X., Li, Q., Krantz, S.B. & Zhao, Z.J. (2005) Identification of an acquired JAK2 mutation in polycythemia vera. The Journal of Biological Chemistry, 280, 2278822792.